15.12
로그선형 모델은 약물 농도와 그 효과 간의 관계를 설명하는 약리학적 모형입니다. 이 모델은 관찰된 효과가 약물의 최대효과, 또는 E_max,의 20%에서 80% 범위에 있을 때 특히 적절하며, 이 구간에서는 약물 농도의 로그값과 측정된 효과 사이에 거의 선형적인 관계가…
로그선형 모델은 효과가 약물 농도의 로그에 정비례한다고 가정합니다.
효과 E는 다음 식으로 주어집니다. 여기서 S 는 단위 약물 농도에 의해 발생하는 효과를, C는 혈장 약물 농도를, E0 은 기준선 효과를 나타냅니다.
최대 효과인 Emax가 20%에서 80% 사이일 때, 약물 농도와 효과의 로그 그래프는 거의 선형적으로 나타납니다.
특히, 이 모델은 약물 농도가 0일 때의 Emax 나 효과를 예측할 수 없다는 점입니다.
하지만 와파린과 프로프라놀롤과 같은 약물의 농도-효과 관계를 예측하는 데 사용됩니다.
예를 들어, 프로프라놀롤의 혈장 농도와 운동 유발 빈맥의 백분 블록 그래프는 정맥 및 경구 경로 모두에서 선형적입니다.
그 결과, 프로프라놀롤 농도를 높이면 운동 유발 빈맥이 효과적으로 줄어들며, 정맥 투여 경로가 더 뚜렷하고 일관된 반응을 보입니다.
View the full transcript and gain access to JoVE Core videos
Q1: What is the log-linear model in pharmacodynamics?
The log-linear model describes the relationship between drug concentration and its effect by assuming the effect is directly proportional to the logarithm of drug concentration. It uses the equation E = S × log(C) + E0, where S represents the effect per unit concentration, C is plasma drug concentration, and E0 is baseline effect. This model is particularly useful when drug effects range between 20% and 80% of maximum effect.
Q2: When is the log-linear model most applicable in drug analysis?
The log-linear model is most applicable when observed drug effects fall between 20% and 80% of the maximum effect (Emax), where the relationship between log drug concentration and effect appears nearly linear. Within this range, the model accurately predicts concentration-effect relationships for drugs like warfarin and propranolol, making it valuable for understanding pharmacodynamic responses in clinical settings.
Q3: What are the limitations of the log-linear pharmacodynamic model?
The log-linear model cannot predict the maximum possible effect (Emax) or the effect at zero drug concentration, limiting its applicability in complete pharmacodynamic analyses. These limitations mean the model is restricted to predicting concentration-effect relationships within the linear range and cannot extrapolate to extreme effect values or baseline conditions.
Q4: How does propranolol concentration affect exercise-induced tachycardia?
Propranolol demonstrates a linear concentration-effect relationship with exercise-induced tachycardia when plotted on a logarithmic scale. Increasing propranolol concentration effectively reduces tachycardia by blocking β-adrenergic receptors. The intravenous route produces more pronounced and consistent responses compared to oral administration due to reduced variability in bioavailability and plasma concentration.
Q5: Why does intravenous propranolol show a more consistent response than oral administration?
Intravenous propranolol administration produces more consistent and pronounced responses because it avoids the variability associated with oral bioavailability and absorption. IV administration results in more predictable plasma concentrations, allowing the log-linear model to accurately describe the concentration-effect relationship. Oral routes introduce additional variables that reduce response consistency.
Q6: Which drugs are effectively modeled using the log-linear concentration-effect approach?
Warfarin and propranolol are primary examples of drugs effectively modeled using the log-linear approach. Both drugs demonstrate linear relationships between log plasma concentration and their pharmacological effects within the 20-80% Emax range. This makes the log-linear model particularly valuable for predicting and understanding the concentration-effect relationships of these commonly used medications.
Q7: How does the log-linear model differ from other pharmacodynamic models?
The log-linear model assumes a linear relationship between log drug concentration and effect, differing from models that describe sigmoidal or non-linear relationships. Unlike the Emax model, the log-linear model cannot predict maximum effect or baseline response. It is specifically designed for the middle range of drug effects and provides a simplified approach to concentration-effect prediction within defined boundaries.